---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332809"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2026-08-04T20:10:16+00:00"
generated_at: "2026-08-04T20:11:08.861746+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OnKure Q2 2026 net loss $15.3M; cash $176.4M funds operations into 2029

## Summary
- Net loss of $15.3M ($0.31 per share) vs $15.4M ($1.14 per share) in Q2 2025.
- Cash, cash equivalents and marketable securities of $176.4M as of June 30, 2026; runway into 2029.
- R&D expenses flat at $12.6M; G&A up $0.6M to $4.3M on higher personnel and consulting costs.
- IND submissions for PI3Kα pan-mutant candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies) planned for 1H 2027.
- Hosted KOL event on PI3Kα selectivity; participated as exhibitor/sponsor at ISSVA World Congress 2026.

## SEC filing metadata
- accession: 0001193125-26-332809
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2026-08-04T20:10:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/0001193125-26-332809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/okur-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332809
- JSON: https://secwatch.observer/filing/0001193125-26-332809.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.